www.humanlongevity.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $91.95MM
Human Longevity is a biotechnology company which offers genomics and data analytics solutions to healthy individuals. This company was founded by J. Craig Venter Ph.D, Peter Diamandis, and Robert Hariri Ph.D in 2013 and is headquartered in San Diego, CA. Human Longevity’s platform includes the Health Nucleus, a comprehensive health assessment that combines whole-gene sequencing, advanced imaging, and other diagnostics aiming to identify potential health risks and develop personalized longevity plans.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
08/21/2024 | Series B-2 | $7.9MM | $xx.xx | $185.79MM | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | |
Price per Share
$xx.xx
Shares Outstanding
30,850,126
Liquidation Pref Order
1
Liquidation Pref As Multiplier
3.0x
Conversion Ratio
3.0x
Dividend Rate
9.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust
|
||||||
08/21/2024 | Series B-1 | $32MM | $xx.xx | $185.79MM | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | |
Price per Share
$xx.xx
Shares Outstanding
102,860,812
Liquidation Pref Order
1
Liquidation Pref As Multiplier
3.0x
Conversion Ratio
3.0x
Dividend Rate
9.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust
|
||||||
11/06/2019 | Series A-2 | $34.06MM | $xx.xx | $50.4MM | Emerging Technology Partners | |
Price per Share
$xx.xx
Shares Outstanding
133,034,522
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Emerging Technology Partners
|
||||||
11/06/2019 | Series A-1 | $18MM | $xx.xx | $50.4MM | Emerging Technology Partners | |
Price per Share
$xx.xx
Shares Outstanding
7,964,602
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.2x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Emerging Technology Partners
|